The remarkable results of KEYNOTE-048 ultimately led to the FDA approval of pembrolizumab plus chemotherapy for all populations and pembrolizumab monotherapy for patients with PD-L1 CPS ≥1 as first line treatment for R/M HNSCC in June of 2019. This evidence concerns the gene CD274 and head and neck squamous cell carcinoma.